(Q38227648)

31 August 2017

title

The potential for renoprotection with incretin-based drugs (English)

1 reference

31 August 2017

Tetsuhiro Tanaka

1

1 reference

31 August 2017

Yoshiki Higashijima

series ordinal

2

1 reference

31 August 2017

Takehiko Wada

series ordinal

3

1 reference

31 August 2017

Masaomi Nangaku

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

9 July 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

86

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

701-711

1 reference

Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Functional implications of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effect of a multifactorial intervention on mortality in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The role of glycemia management in the prevention of cardiovascular disease--starting over?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

cAMP-GEFII is a direct target of cAMP in regulated exocytosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The effect of glucagon-like peptide 1 on cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Demonstration of glomerular DPP IV activity in kidney diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Primary graft dysfunction in lung transplantation: the role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Peptidase substrates via global peptide profiling

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemia-reperfusion injury in mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The multifunctional or moonlighting protein CD26/DPPIV.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Regulation of Nox1 activity via protein kinase A-mediated phosphorylation of NoxA1 and 14-3-3 binding.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Exenatide improves hypertension in a rat model of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2014.236

7 January 2021

Identifiers

DOI

10.1038/KI.2014.236

1 reference

Dimensions Publication ID

31 August 2017

1008487451

0 references

1 reference